Physician profile
Jennifer Bacci
NPI 1225625122
$2,651.98
in general payments reported to CMS, 2019-2025
31 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.23 · 2022: $226 · 2023: $222 · 2024: $584 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $366.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $296.23 | 2025 | |
| Janssen Biotech, INC. | $265.75 | 2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $225.38 | 2022-2025 | Omvoh, Zepbound, Mounjaro |
| Kerecis Limited | $223.58 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Novo Nordisk INC | $112.56 | 2021-2024 | Wegovy |
| Baxter Healthcare | $108.00 | 2023-2024 | Perclot, Floseal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.62 | 2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $99.32 | 2022-2025 | Contrave |
| Ardelyx, INC. | $96.65 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $78.25 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $75.11 | 2025 | |
| Qol Medical, LLC | $75.10 | 2025 | Sucraid |
| Teleflex LLC | $73.56 | 2022-2024 | Titan Sgs |
| Endo Pharmaceuticals INC. | $73.25 | 2022-2023 | Nascobal |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $64.06 | 2022-2024 | Stratafix |
| Ipsen Biopharmaceuticals, INC | $51.55 | 2025 | Iqirvo |
| Exact Sciences Corporation | $26.75 | 2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $24.76 | 2024 | Phasix Mesh |
| Medtronic, INC. | $22.50 | 2022 | |
| Convatec INC. | $21.01 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.15 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $19.79 | 2025 | Dupixent |
| Boston Scientific Corporation | $17.17 | 2023 | Watchman |
| Tela Bio, INC. | $16.92 | 2024 | Ovitex 2s |
| Apollo Endosurgery US INC | $16.68 | 2022 | |
| Aimmune Therapeutics, INC. | $15.48 | 2025 | Zenpep |
| Vivus LLC | $15.38 | 2025 | Qsymia |
| Daiichi Sankyo INC. | $15.00 | 2022 | |
| Braintree Laboratories, INC. | $14.61 | 2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bacci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.